Emotions in Multiple Sclerosis

NCT ID: NCT04804787

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-23

Study Completion Date

2025-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Through this study, a group composed of multiple sclerosis patients will be compared to a healthy volunteers group to determine if the positive emotions recognitions is preserved in the first group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Different studies have highlighted the specific deficiency concerning emotions recognition in multiple sclerosis. Patients with multiple sclerosis are reported to have more difficulty recognising negative emotions, especially anger and fear.

In this context, RECODE study has a twofold objective:

* To determine whether the positive emotions recognition remains preserved by combining behavioural and neurophysiological measures (electrodermal activity).
* To study this disorder's etiology through a comparison between a multiple sclerosis patient group and a control group (matched in sex, age, and education's level).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Multiple sclerosis Emotions recognition Cognitive disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

1 experimental group composed of patients with multiple sclerosis

1 control group composed of volunteers matched in gender, age, and education's level with the experimental group
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group : patients with multiple sclerosis

The experimental group will be constituted of patients with multiple sclerosis.

Group Type EXPERIMENTAL

Carrying out a tests and questionnaires battery

Intervention Type DIAGNOSTIC_TEST

The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders

Control group : volunteers

The control group will be constituted of healthy volunteers with the same characteristics concerning age, sex, education's level as experimental group's patients

Group Type ACTIVE_COMPARATOR

Carrying out a tests and questionnaires battery

Intervention Type DIAGNOSTIC_TEST

The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carrying out a tests and questionnaires battery

The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female between 18 and 55 years old.
* Understand and able to express themselves in French.
* EXPERIMENTAL GROUP :
* Relapsing-remitting form (RRMS)
* With an EDSS \< 4 (Expanded Disability Status Scale)
* No significant motor, cerebellar or somatosensory disorders of the upper limbs or visual disorders (EDSS specific parameter \<2)
* No flare-up in the last 6 weeks
* No corticosteroids taken in the last 4 weeks
* CONTROL GROUP :
* Lack of global cognitive deterioration (according to Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) standards).
* Gender, age and education level matching to the multiple sclerosis patients
* Understanding and signing the informed consent and information letter regarding participation in the study.
* Benefiting from health insurance coverage.

Exclusion Criteria

* Persons with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, perceptive or dysarthric disorders preventing verbal communication or reading,
* People with sensory disorders (visual and auditory) that interfere with the performance of neuropsychological tests;
* Treatment with psychotropic drugs (except benzodiazepines and hypnotics).
* Refusal to participate after clear and fair information about the study.
* Major persons under guardianship, under judicial protection, persons deprived of liberty.
* Pregnant or breastfeeding women
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lille Catholic University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno Lenne

Role: PRINCIPAL_INVESTIGATOR

Hôpital Saint Vincent de Paul, Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Saint-Vincent de Paul

Lille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC-P00107

Identifier Type: -

Identifier Source: org_study_id